Syndax Pharmaceuticals (SNDX) EBT Margin (2015 - 2026)
Syndax Pharmaceuticals (SNDX) recorded quarterly EBT Margin of 47.24% in Q1 2026, up 44.24% quarter-over-quarter from 84.71% in Q4 2025, and up 33484.0% on a YoY basis from N/an in Q1 2025.
Syndax Pharmaceuticals (SNDX) EBT Margin (2015 - 2026) Analysis & Trends
Syndax Pharmaceuticals' EBT Margin history runs 10 years deep, the most recent figure standing at 47.24% for Q1 2026.
- In Q1 2026, EBT Margin rose 33484.0% year-over-year to 47.24%; the TTM figure through Mar 2026 stood at 94.02% (up 63294.0% YoY), while the FY2025 annual figure was 145.26%, up 117898.0% from the prior year.
- EBT Margin was 47.24% for Q1 2026 at Syndax Pharmaceuticals, up from 84.71% in the prior quarter.
- In the past five years, EBT Margin ranged from a high of 47.24% in Q1 2026 to a low of 1942.2% in Q2 2024.
- Historically, EBT Margin has averaged 571.35% across 3 years, with a median of 274.56% in 2025.
- The sharpest annual moves came in 2025 and 2026: EBT Margin jumped 177515 bps in 2025, then soared 33484 bps in 2026.
- A 3-year view of EBT Margin shows it stood at 1160.59% in 2024, then soared by 93 bps to 84.71% in 2025, then jumped by 44 bps to 47.24% in 2026.
- The last three EBT Margin figures came in at 47.24% (Q1 2026), 84.71% (Q4 2025), and 113.7% (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 6.40% |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 41.95% |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | - |
| 10 | Syndax Pharmaceuticals | 1.69 Bn | 1.34 Bn | 53.02 Mn | -47.24% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -47.24% |
| Dec 31, 2025 | -84.71% |
| Sep 30, 2025 | -113.70% |
| Jun 30, 2025 | -167.05% |
| Mar 31, 2025 | -382.08% |
| Dec 31, 2024 | -1,160.59% |
| Sep 30, 2024 | -673.26% |
| Jun 30, 2024 | -1,942.20% |
| Dec 31, 2021 | 75.72% |
| Sep 30, 2021 | -166.45% |
| Jun 30, 2021 | -6,031.66% |
| Mar 31, 2021 | -7,299.74% |
| Dec 31, 2020 | -5,365.53% |
| Sep 30, 2020 | -5,359.10% |
| Jun 30, 2020 | -4,491.56% |
| Mar 31, 2020 | -4,014.78% |
| Dec 31, 2019 | -3,679.74% |
| Sep 30, 2019 | -3,365.17% |
| Jun 30, 2019 | -3,924.27% |
| Mar 31, 2019 | -3,788.65% |